Corporate / M&A

Employment and Executive Compensation

addex Therapeutics

Homburger News

Share-Image Teamplate Deals-and-Cases

Homburger advised Addex Therapeutics Ltd

On April 3, 2024, Addex Therapeutics, a clinical-stage biopharmaceutical company, listed on the SIX Swiss Exchange and on the Nasdaq, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
With initial funding of USD 63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex in view of accelerating their development. In return, Addex received CHF 5 million and a 20% equity interest in Neurosterix. Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough.
Homburger advised Addex in this transaction. The Homburger team comprised Frank Gerhard, Romain Fakhoury, Fabio Gasser, Paula Delissen (all Corporate / M&amp;A), Jeremy Reichlin (Employment) and Peter Müller (Tax).

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

IP / IT

Competition

Regulatory

Cadence-webnews

Candence Design Systems Inc. aquires BETA CAE Systems

Homburger advises Cadence on its  USD 1.24 bn acquisition of BETA CAE Systems

On March 5, 2024, Cadence Design Systems Inc. (Nasdaq: CDNS), a leading global EDA and Intelligent System Design provider, announced that it has signed a definitive agreement to acquire BETA CAE Systems International AG, a leading provider of multi-domain, engineering simulation solutions headquartered in Switzerland.
Under the terms of the definitive agreement, Cadence will pay approximately USD 1.24 bn for the transaction, with 60 percent of the consideration to be paid in cash and 40 percent to be paid through the issuance of Cadence common stock to current BETA CAE shareholders. The transaction, which is subject to customary conditions, is expected to close in the second quarter of this year.
Homburger advises Cadence Design Systems Inc. on the Swiss aspects of the transaction. The Homburger team is led by Daniel Hasler and includes Léonard Aeschlimann, Bianca Nedwed, Daniel Bötticher, Paula Delissen and Luc Huber (all Corporate / M&amp;A), Gregor Bühler and Kimberly Amrein (both Employment and Executive Compensation), Kirsten Wesiak-Schmidt and Marc Wang (both IP / IT), Jonas Krull (Competition, Regulatory), as well as Peter Müller (Tax).

Paula
Delissen

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises Cadence on its USD 1.24 bn acquisition of BETA CAE Systems

Join the Team

Paula Delissen

Career

Languages

Bar Registration

Teams

PaulaDelissen

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises Cadence on its USD 1.24 bn acquisition of BETA CAE Systems

Join the Team

Paula Delissen

Career

Languages

Bar Registration

Teams

Paula
Delissen